Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS

Onconetix, Inc. ONCO

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$815,371
▼ 67.7% YoY
$-14.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Through its acquisition of Proteomedix, which closed on December 15, 2023, the company owns Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation (IVDR). ENTADFI is an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of BPH, a disorder of the prostate. The company is currently focusing its efforts on commercializing Proclarix. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient's regular Prostate-Specific Antigen (PSA) test. Proclarix is CE-marked and for sale in Europe.

Written from the business description in Onconetix, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 13 March 2026. Every sentence was checked against that document before publication.

Growth

USD 815,371.00
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.8 · Net income -14.0
-25.0M-50.0M
202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -2190.0%
-20000%-40000%-60000%
202120232025
ROE
FY2025 · ROE -115.5%
-100%-200%
202120232025
Three returns, three denominators.

Each USD of equity lost 115 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -10.5
-5M-10M
202120232025
Net buybacks $ Dividends $
FY2022 · Dividends · · Net buybacks 565155.0
200000400000
2022

Total assetsUSD 24.9M
CashUSD 5.2M
Current ratio0.66×

Not available: we don't have the total debt figure for this period.

The 5-year record

5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ONCO, 5-year financial record
Metric 20252024202320222021
Revenue $B0.00.00.0◌◌
Operating income $B−0.0−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.0−0.0−0.0
Income tax $B0.0−0.0−0.03158.9675.7
Net income $B−0.0−0.1−0.0−0.0−0.0
Free cash flow $B◌−0.0−0.0−0.0−0.0
EPS, diluted $−16.56−1823.39−87.45−1.10−1.26
Dividend / sh $◌◌◌1.23◌
Payout % — not applicable: no dividend—————
ROE %−115.5——−112.6−236.2
Shares out B0.000.000.020.020.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 23 reconciliationsAUDITED

Reconciled in 5 of the 5 fiscal years we could check. 28 checks were skipped: the balance sheet is not tagged before 2021. 16 checks were skipped: revenue is not tagged before 2023. 14 checks were skipped: EPS is not tagged before 2021.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2021

Share this section

Download image